Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia

Journal of Infection in Developing Countries

Volumn 9, Issue 5, 2015, Pages 476-485

  Yilmaz, Gul Ruhsar ^a   Guven, Tumer ^b   Guner, Rahmet ^b   Tufan, Zeliha Kocak ^b   Izdes, Seval ^b   Tasyaran, Mehmet A ^b   Açıkgöz, Ziya Cibali ^b  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

A. baumannii; Colistin; Combined antibiotics; Ventilator associated pneumonia

Indexed keywords

CARBAPENEM; COLISTIN; IMIPENEM; MEROPENEM; SULBACTAM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ADULT; ARTICLE; CLINICAL ASSESSMENT; DISK DIFFUSION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INHIBITION ZONE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MICROBIAL IDENTIFICATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER INFECTIONS; AGED; CHEMICALLY INDUCED; DRUG EFFECTS; ISOLATION AND PURIFICATION; KIDNEY FAILURE; MICROBIOLOGY; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SULBACTAM; TREATMENT OUTCOME;

EID: 84929579048     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.6195     Document Type: Article

References (41)

1. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME (2005) Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49: 3136-3146.
2. Kalin G, Alp E, Akin A, Coskun R, Doganay M (2014) Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 42: 37-42.
3. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56: 432-436.
4. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M (2007) Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 33: 1162-1167.
5. Durante-Mangoni E, Utili R, Zarrilli R (2014) Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date. Future Microbiol 9: 773-789.
6. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50: 2946-2950.
7. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, Nation RL, Li J (2009) Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 58: 138-144.
8. American Thoracic Society and Infectious Disease Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416.
9. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309-332.
10. Bergmans CJJD, Bonten MJM (2012) Healthcare-Associated Pneumonia. In Mayhall CG, editor. Hospital Epidemiology and Infection Control. Philadelphia: Lippincott Williams & Wilkins. 307-320.
11. Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing; 21th informational supplement, M100-S21. CLSI: Wayne, PA.
12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 266-281.
13. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57: 349- 358.
14. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A (2005) Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 5: 1.
15. Gales AC, Jones RN, Sader HS (2011) Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 66: 2070-2074.
16. Guven T, Yilmaz GR, Guner HR, Kaya-Kalem A, Civelek Eser F, Tasyaran MA (2014) Increasing resistance of nosocomial Acinetobacter baumannii: Are we going to be defeated? Turk J Med Sci 44: 73-78.
17. Michalopoulos A, Falagas ME (2008) Colistin and polymyxin B in critical care. Crit Care Clin 24: 377-391.
18. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36: 1111-1118.
19. Falagas ME, Kasiakou SK, Michalopoulos A (2005) Treatment of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii pneumonia. J Cyst Fibros 4: 149-150.
20. Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G, Martins G, Das Neves A, Santander O, Ramos C (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31: 1058-1065.
21. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A, Hatzopoulou P, Michalopoulos A (2006) Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect 12: 1227-1230.
22. Chan JD, Graves JA, Dellit TH (2010) Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 25: 343-348.
23. Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM (2012) Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents 39: 180-181.
24. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA (2002) Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 34: 1425-1430.
25. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, Orengo G, Bobbio Pallavicini F, Viscoli C (2008) Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61: 417-420.
26. Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M (2013) In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. J Int Med Res 4: 1830-1837.
27. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ (2007) In vitro activities of carbapenem/sulbactamcombination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60: 317-322.
28. Rodríguez-Hernández MJ, Cuberos L, Pichardo C, Caballero FJ, Moreno I, Jiménez-Mejías ME, García-Curiel A, Pachón J (2001) Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 47: 479-482.
29. Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, Chuang YC (2004) In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 53: 393-395.
30. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, Pujol M, Gudiol F (1998) Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 42: 793-802.
31. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G (2007) High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii.Scand J Infect Dis 39: 38-43.
32. Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A (2014) Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 43: 378-382.
33. Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J (2013) Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 17: 389-394.
34. Petrosillo N, Ioannidou E, Falagas ME (2008) Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 14: 816-827.
35. Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, Leelarasamee A (2010) Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii. J Med Assoc Thai 93: 161-171.
36. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A (2010) Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35: 194-199.
37. Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ (2011) Clinical and microbiological characterization of carbapenem resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol 60: 605–611.
38. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H (2014) Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 33: 1311-1322.
39. Kuo SC, Lee YT, Yang SP, Chiang MC, Lin YT, Tseng FC, Chen TL, Fung CP (2013) Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomial bacteraemia. Clin Microbiol Infect 19: 634-639.
40. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H (2001) Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 40: 117-120.
41. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME (2005) Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11: 115-121.